Crizanlizumab is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to GlobalData, Phase II drugs for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Crizanlizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Crizanlizumab overview
Crizanlizumab-TMCA (Adakveo, Chylotrez) is a monoclonal antibody, produced by using recombinant DNA technology in chinese hamster ovary (CHO) cells. It is formulated as solution and concentrate solution for intravenous route of administration. Adakveo is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
Crizanlizumab (SEG101, SelG-1) is under development for the treatment of sickle cell disease, vaso-occlusive crisis associated with sickle cell disease. chronic kidney disease due to sickle cell nephropathy and primary myelofibrosis including post-essential thrombocythemia (ET) (PET-MF), post-polycythemia vera (PV) myelofibrosis (PPV-MF) and COVID-19 vasculopathy. The therapeutic candidate is administered as an intravenous infusion. It is a humanized monoclonal antibody that acts by targeting P-selectin.
Novartis overview
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Crizanlizumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
